局灶性癫痫服用吡仑帕奈致皮疹病例报道并文献学习_Journal of Epilepsy

Authors：

王碧 , 张歆博 ,  刘永红

1. ;

Corresponding author：

刘永红, Email: liuyhong@fmmu.edu.cn

Keywords：

吡仑帕奈; 药物不良反应; 皮疹

DOI：

10.7507/2096-0247.202401004

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 王碧, 张歆博, 刘永红. 局灶性癫痫服用吡仑帕奈致皮疹病例报道并文献学习. Journal of Epilepsy, 2024, 10(2): 155-157. doi: 10.7507/2096-0247.202401004 Copy

1.	Johannessen L, Johannessen S, Patsalos P. Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects. Expert Opin Drug Metab Toxicol, 2020, 16(3): 227-238.
2.	Singh K, Verma N. Teratogenic potential of third-generation antiepileptic drugs: current status and research needs. Pharmacol Rep, 2019, 71(3): 491-502.
3.	Nishida T, Lee S, Wu T, et al. Efficacy and safety of perampanel in generalized and focal to bilateral tonic-clonic seizures: a comparative study of Asian and non-Asian populations. Epilepsy, 2019, 60(Suppl1): 47-59.
4.	Ettinger A, Lopresti A, Yang H, et al. Psychiatric and behavioral adverse events in randomized clinical studies of the non-competitive AMPA receptor antagonist perampanel. Epilepsy, 2015, 56(8): 1252-1263.
5.	张捷, 谢涵, 邓泂, 等. 基于随访6个月疗效结局的加用吡仑帕奈治疗儿童药物难治性癫痫的单中心前瞻性队列研究. 中国循证儿科杂志, 2021, 16(4): 269-274.
6.	Yelshanskaya M, Singh A, Sampson J, et al. Structural bases of ampa-subtype iono-tropic glutamate receptors by antiepileptic drugs. Neuron, 2016, 91(6): 1305-1315.
7.	孟林雪. 吡仑帕奈的抗癫痫作用机制及临床应用. 癫痫与神经电生理学杂志, 2021(6): 321-326.
8.	Pina-Garza JE, Rosenfeld W, Saeki K, et al. Efficacy and safety of adjunctive parampanelin adolescent patients with epilepsy: post hoc analysis of six randomized studies. Epilepsy Behav, 2020, 104 (Pt A): 106876.
9.	Rektor I, Krauss G, Inoue Y, et al. Assessment of the long term efficacy and safety of adjunctive peampanel in tonic-clonicseizures: analysis of four open label extension studies. Epilepsy, 2020, 61(7): 1491-1502.
10.	Knowles S, Shapirole, Shear N. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drllg Saf, 1999, 21(6): 489-501.
11.	Sehlienger R, Shear N. Antiepileptic drug hypersensitivity syndrome Epilepsy, 1998, 39(Suppl 7): S3-S7.
12.	WHO—UMC. The use of the WHO-UMC system for standardised case causality assessment. [EB/OL]. 2009-07-03[2009-3-0l.
13.	Wood M, Gillard M. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptievesiele 2A protein Epilepsy, 2017, 58(2): 255-262.
14.	陈娇, 刘晓鸣, 岳璇. 左乙拉西坦添加治疗对难治性癫痫患儿外周血多药耐药相关蛋白1、2表达的影响. 中华实用儿科临床杂志, 2017, 32(22): 1737-1740.
15.	Arif H, Uchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology, 2007, 68(20): 1701-1709.
16.	张夏婷, 刘刚, 孙伟. 左乙拉西坦致皮疹2例. 药物不良反应杂志, 2011, 13(6): 391-392.
17.	Svendsen T, Brodtkorb E, Baftiu A, et al. Clinical experience combined with therapeutic drug monitoring of lacosamide. Acta Neurologica Scandinavica, 2020, 141(4): 279-286.
18.	Cawello W, Stockis A, Andreas J, et al. Advances in epilepsy treatment: lacosamide pharmacokinetic pofile. Ann N Y Acad sci, 2014, 1329: 18-32.
19.	Cawello W. Clinical pharmacokinetic and pharmacodynamic profile of lacosamide. Clin Pharmacokinct, 2015, 54(9): 90l-914.
20.	Biton V, Nagel A, Isojarvi J, et al. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: analysis of data pooled from three randomized, double blind, placebo-controlled clinical trials. Epilepsy Behav, 2015, 52(2): 119-127.
21.	刘平, 吴茵, 何伟亮, 等. 吡仑帕奈抗癫痫的药理作用和临床评. 中国新药与临床杂志, 2022, 41(3): 138-142.
22.	Deliso P, Moavero R, Coppola G, et al. Current role of perampanel in Pediatric epilepsy. Ital J Pediatric, 2017, 43(1): 51.

1. Johannessen L, Johannessen S, Patsalos P. Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects. Expert Opin Drug Metab Toxicol, 2020, 16(3): 227-238.
2. Singh K, Verma N. Teratogenic potential of third-generation antiepileptic drugs: current status and research needs. Pharmacol Rep, 2019, 71(3): 491-502.
3. Nishida T, Lee S, Wu T, et al. Efficacy and safety of perampanel in generalized and focal to bilateral tonic-clonic seizures: a comparative study of Asian and non-Asian populations. Epilepsy, 2019, 60(Suppl1): 47-59.
4. Ettinger A, Lopresti A, Yang H, et al. Psychiatric and behavioral adverse events in randomized clinical studies of the non-competitive AMPA receptor antagonist perampanel. Epilepsy, 2015, 56(8): 1252-1263.
5. 张捷, 谢涵, 邓泂, 等. 基于随访6个月疗效结局的加用吡仑帕奈治疗儿童药物难治性癫痫的单中心前瞻性队列研究. 中国循证儿科杂志, 2021, 16(4): 269-274.
6. Yelshanskaya M, Singh A, Sampson J, et al. Structural bases of ampa-subtype iono-tropic glutamate receptors by antiepileptic drugs. Neuron, 2016, 91(6): 1305-1315.
7. 孟林雪. 吡仑帕奈的抗癫痫作用机制及临床应用. 癫痫与神经电生理学杂志, 2021(6): 321-326.
8. Pina-Garza JE, Rosenfeld W, Saeki K, et al. Efficacy and safety of adjunctive parampanelin adolescent patients with epilepsy: post hoc analysis of six randomized studies. Epilepsy Behav, 2020, 104 (Pt A): 106876.
9. Rektor I, Krauss G, Inoue Y, et al. Assessment of the long term efficacy and safety of adjunctive peampanel in tonic-clonicseizures: analysis of four open label extension studies. Epilepsy, 2020, 61(7): 1491-1502.
10. Knowles S, Shapirole, Shear N. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drllg Saf, 1999, 21(6): 489-501.
11. Sehlienger R, Shear N. Antiepileptic drug hypersensitivity syndrome Epilepsy, 1998, 39(Suppl 7): S3-S7.
12. WHO—UMC. The use of the WHO-UMC system for standardised case causality assessment. [EB/OL]. 2009-07-03[2009-3-0l.
13. Wood M, Gillard M. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptievesiele 2A protein Epilepsy, 2017, 58(2): 255-262.
14. 陈娇, 刘晓鸣, 岳璇. 左乙拉西坦添加治疗对难治性癫痫患儿外周血多药耐药相关蛋白1、2表达的影响. 中华实用儿科临床杂志, 2017, 32(22): 1737-1740.
15. Arif H, Uchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology, 2007, 68(20): 1701-1709.
16. 张夏婷, 刘刚, 孙伟. 左乙拉西坦致皮疹2例. 药物不良反应杂志, 2011, 13(6): 391-392.
17. Svendsen T, Brodtkorb E, Baftiu A, et al. Clinical experience combined with therapeutic drug monitoring of lacosamide. Acta Neurologica Scandinavica, 2020, 141(4): 279-286.
18. Cawello W, Stockis A, Andreas J, et al. Advances in epilepsy treatment: lacosamide pharmacokinetic pofile. Ann N Y Acad sci, 2014, 1329: 18-32.
19. Cawello W. Clinical pharmacokinetic and pharmacodynamic profile of lacosamide. Clin Pharmacokinct, 2015, 54(9): 90l-914.
20. Biton V, Nagel A, Isojarvi J, et al. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: analysis of data pooled from three randomized, double blind, placebo-controlled clinical trials. Epilepsy Behav, 2015, 52(2): 119-127.
21. 刘平, 吴茵, 何伟亮, 等. 吡仑帕奈抗癫痫的药理作用和临床评. 中国新药与临床杂志, 2022, 41(3): 138-142.
22. Deliso P, Moavero R, Coppola G, et al. Current role of perampanel in Pediatric epilepsy. Ital J Pediatric, 2017, 43(1): 51.

Journal of Epilepsy

局灶性癫痫服用吡仑帕奈致皮疹病例报道并文献学习

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content